Charlotte M. Harvey

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama et al. · The Lancet · 2007 · 568 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Infectious Diseases +16

Differentiation of Angiotensin–Converting Enzyme (ACE) Inhibitors by Their SelectiveInhibition of ACE in Physiologically Important Target Organs

David W. Cushman, F. L. Wang, Wing Chiu Fung et al. · American Journal of Hypertension · 1989 · 197 citations

Medicine, Pharmacokinetics, Pharmacology +15

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)

David L. Paterson, Flávia Rossi, Fernando Baquero et al. · Journal of Antimicrobial Chemotherapy · 2005 · 185 citations

Veterinary Medicine, Infectious Diseases, Microbiology +7

Effects of Omeprazole on Plasma Levels of Raltegravir

Marian Iwamoto, Larissa Wenning, Bach‐Yen Nguyen et al. · Clinical Infectious Diseases · 2009 · 86 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

José M. Gatell, Christine Katlama, Beatriz Grinsztejn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 63 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17